SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) — The Shareholders Foundation, Inc. announced an update to the lawsuit filed for certain investors in Instadose Pharma Corp. stock. (OTC: INSD) is pending.

Investors who bought Instadose Pharma Corp. shares before December 2020. (OTC: INSD) and continue to hold any of these OTC: INSD shares also have certain options and should contact the Shareholders Foundation at [email protected] or by phone at +1(858) 779-1554.

On December 20, 2021, a lawsuit filed against certain investors in OTC: INSD stocks against Instadose Pharma Corp. f/k/a Mikrocoze, Inc. filed for alleged violations of securities laws. Plaintiff alleged that Defendants provided false and/or misleading information and/or failed to disclose that Instadose performed insufficient due diligence on the business combination and/or ignored significant red flags related to Instadose Canada, that internal controls and Instadose’s policies were insufficient to detect and/or prevent improper trading activities by company controllers, that the foregoing exposed Instadose to increased risk of regulatory scrutiny and enforcement action, and that the company’s public statements were, as a result, materially false and misleading at times.

On August 24, 2022, Plaintiff sought a notice of default against Defendants for failure to show up in a timely manner or to respond to the complaint.

On August 25, the court clerk made a default entry in the file for both defendants.

Those who own shares of Instadose Pharma Corp. (OTC: INSD) should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement filing service that conducts research on shareholder matters and keeps investors informed of securities class actions, settlements, judgments and other stock/financial market legal news. The shareholders…